Usefulness of compounds with monacolin K in a case of statins intolerance

  1. Parra-Virto, Alejandro
  2. Torres do Rego, Ana
  3. Demelo-Rodríguez, Pablo
  4. Millán Núñez-Cortés, Jesús
  5. Álvarez-Sala, Luis A.
Aldizkaria:
Clínica e investigación en arteriosclerosis

ISSN: 0214-9168,  1578-1879

Argitalpen urtea: 2018

Alea: 30

Zenbakia: 6

Orrialdeak: 268-270

Mota: Artikulua

DOI: HTTPS://DOI.ORG/10.1016/J.ARTERI.2018.06.003 DIALNET GOOGLE SCHOLAR

Beste argitalpen batzuk: Clínica e investigación en arteriosclerosis

Laburpena

Many patients with familial hypercholesterolaemia (FH) or in secondary prevention situations and with statin intolerance do not achieve LDL-C targets, and require treatment with PCSK9 inhibitors (iPCSK9) and ezetimibe. The case is presented on a patient with FH and total intolerance to statins. Treatment with iPCSK9 and ezetimibe failed to achieve her LDL-C target. A compound with red yeast rice derivatives containing 3 mg of monacolin K was added, with good therapeutic compliance, and a very good control of LDL-C. The addition of red yeast rice derivatives containing low doses of monacolin K, together with IPCSK9 in patients with total intolerance to statins, may open a new path to obtain LDL-C targets in patients with high/very high cardiovascular risk.

Datuen iturria: Dialnet